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Abstract: Macular edema (ME) is a common cause of visual loss among eyes with uveitis, and
its management can be challenging. Steroids are an effective treatment for ME, and intravitreal
dexamethasone (DEX) implants provide sustained steroid release. The purpose of this study is to
evaluate intravitreal DEX implant on refractory ME in eyes with noninfectious uveitis. A retrospective
study including 52 eyes of 37 patients with refractory uveitic ME was conducted from January 2011
through August 2017 at Linkou Chang Gung Memorial Hospital in Taiwan. Patients’ demographic
characteristics were collected. In addition, clinical information, including corrected visual acuity
(VA), intraocular pressure (IOP), and central retinal thickness (CRT) on optical coherence tomography,
was recorded and analyzed. During the study period, affected eyes received a total of 110 intravitreal
DEX implants (range, one to six in each eye). After the first DEX implant injection in all eyes, VA
significantly improved at one and two months. CRT significantly decreased one month after a single
DEX implant, and the effect lasted for six months and waned over time. Patients receiving multiple
DEX implants still showed significant decreases in CRT one month after the first implant. Increases
in IOP were noted one month after the DEX implant, but the IOP could be medically controlled.
Intravitreal DEX implants can effectively treat refractory uveitic ME, improving both VA and CRT
with an acceptable safety profile. Further studies are necessary to evaluate the effect of multiple
implants and long-term outcomes.
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Noninfectious uveitis is an inflammatory ocular disease, which is the leading cause of
visual impairment in developed countries and responsible for about 20% of legal blindness [1]. In addition, macular edema (ME) is a significant risk factor for visual loss in eyes
with uveitis, decreasing visual acuity (VA) to <20/40 in about one-third of posterior uveitis
patients [2,3].
Treatment of noninfectious uveitis is mainly focused on suppressing inflammation.
Immunosuppression with medications including antimetabolites and immunomodulatory
agents [4] can also control intraocular inflammation but can have systemic side effects and
variable success in treating ME. Systemic, topical, periocular, and intraocular steroids have
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been widely used to treat uveitis due to their fast and effective anti-inflammatory properties [5,6]. Although systemic corticosteroids have been used in patients with severe uveitis,
they are generally associated with side effects, including osteoporosis, hyperglycemia, arterial hypertension, weight gain, glaucoma, and cataract formation. Treatment with topical
steroids has several disadvantages compared to other ways of administration, including
the requirement of frequent application, preservatives-induced toxicity to the ocular surface, and the inability to access the posterior structures of the eye [7]. Both sub-tenon and
intraocular steroid injections help treat uveitis and uveitis-associated ME [8].
Intravitreal dexamethasone (DEX) implants (Ozurdex, Allergan, Irvine, CA, USA)
have been used since 2009 for the treatment of different ocular diseases such as retinal vein
occlusion [9], uveitis [10], and diabetic ME [11]. The implant is a biodegradable polymer
composed of a combination of 0.7 mg dexamethasone and poly (lactic-co-glycolic acid) [12].
Administered through an intravitreal injection, the implant slowly dissolves in the vitreous
cavity and provides sustained release of DEX for up to six months [13–15].
A clinical trial evaluating the safety and effectiveness of DEX implants in patients
with noninfectious posterior uveitis showed that, after six months, VA was significantly
improved [16]. In addition, other clinical trials have shown that DEX implants are also effective in uveitic ME and for the treatment of uveitis combined with systemic therapy [13–15].
However, there is limited research looking into intravitreal DEX implants for refractory
ME in uveitis. Therefore, the purpose of this study was to evaluate the effects of DEX
intravitreal implants in the eyes of patients with refractory ME due to noninfectious uveitis.
2. Materials and Methods
2.1. Study Design and Population
A retrospective case series study was conducted at Linkou Chang Gung Memorial
Hospital Uveitis Service from January 2011 to August 2017. The study included patients
with DEX implantations for uveitic ME and excluded patients with active uveitis with DEX
implantation. The patients without an anti-inflammatory agent before DEX implantation
were also excluded. The study included a total of 110 intravitreal DEX implants administered to 52 eyes from 37 patients with ME refractory to topical and/or systemic medical
treatments in inflammatory controlled noninfectious uveitis. All patients had received
topical (including eye drops or posterior sub-tenon injection) or systemic steroid therapy
and the refractory uveitic ME in this study was defined as the persistent ME after uveitis
was completely controlled. The treatments before DEX implants are shown in Table 1;
49, 19, and 41 of the 52 eyes had systemic steroid therapy, topical steroid eye drops, and
posterior sub-tenon triamcinolone injection, respectively. If ME persisted after systemic or
topical steroid cessation, DEX implants were used. Of note, 34 of the 52 eyes included in the
study were undergoing disease-modifying antirheumatic drug (DMARD) administration
along with DEX implants. Twenty-seven patients were women, and the mean age of all
participants was 37 (range, 11–73 years old) at the time of the first injection (baseline).
The study was approved by the Chang Gung Memorial Hospital Institutional Review
Board (No. 201302539B0) and performed in compliance with regulatory obligations, the
Declaration of Helsinki, and the institutional review board.
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Table 1. Baseline demographics of patients treated with intravitreal dexamethasone implantation.
Characteristics

Value

No. of patients
No. of eyes
Age (years), mean ± SD (medium, min–max)
Follow-up time (months), mean ± SD
(medium, min–max)
Sex, no. of patients (%)
Female
Male
Disease, no. of eyes (%)
Idiopathic uveitis
Behcet’s disease
Juvenile idiopathic arthritis
Vogt–Koyanagi–Harada syndrome
Acute anterior uveitis
Sarcoidosis
Sympathetic ophthalmia
Ulcerative colitis
Multiple sclerosis
Treatment prior to dexamethasone
implantation, no. of eyes (%)
Systemic steroid therapy
Topical steroid eye drops
Posterior sub-tenon triamcinolone injection
Disease-modifying antirheumatic drugs
Trabeculectomy, no. of eyes (%)
Pseudophakia, no. of eyes (%)
No of dexamethasone implantation, no. of eyes
(%)
1
2
3
>3
Baseline LogMAR VA, mean ± SD (medium,
min–max)
Baseline IOP (mmHg), mean ± SD (medium,
min–max)
Baseline CRT (µm), mean ± SD (medium,
min–max)

37
52
39.3 ± 18.4 (39, 11–74)
11.5 ± 6.9 (11, 3–24)
27 (73.0)
10 (27.0)
18 (34.6)
9 (17.3)
7 (13.5)
5 (9.6)
5 (9.6)
3 (5.7)
2 (3.8)
2 (3.8)
1 (1.9)

49 (94.2)
19 (36.5)
41 (78.8)
34 (65.4)
1 (1.9)
33 (64.7)

24 (46.2)
15 (28.8)
7 (13.5)
6 (11.5)
0.81 ± 0.35 (0.82, 0.30–2.00)
13.3 ± 4.1 (13, 6–25)
507.5 ± 121.7 (512, 267–792)

SD: standard deviation, VA: visual acuity, IOP: intraocular pressure, CRT: central retinal thickness.

2.2. Patient Information and Outcome Measurements
Patients’ characteristics and clinical information including, sex, age, uveitis-causing
disease, treatment, and the number of intravitreal DEX implants, were recorded. In patients with more than one DEX implant, the interval between injections was at least six
months. The outcomes under consideration in this study were best-corrected VA (BCVA),
central retinal thickness (CRT), and intraocular pressure (IOP). BCVA measurements were
converted to the LogMAR (logarithm of the minimum angle of resolution) VA scale for
statistical analysis. CRT was measured by optical coherence tomography (OCT) (Spectralis,
Heidelberg Engineering, Franklin, MA, USA) and determined as the average retinal thickness within the central fovea circle of a 500 µm radius. IOP was measured by tonometry
(Tono-Pen, Reichert, Depew, NY, USA). The outcomes were measured at baseline and one,
two, three, and six months after the implant. The baseline means for LogMAR VA, CRT,
and IOP were 0.81 (range, 0.3–2.0), 507.5 µm (range, 267–792 µm), and 13.3 mmHg (range,
6–25 mmHg), respectively.
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2.3. Statistical Analyses
For the time-varying changes in ocular biomarkers (i.e., VA, CRT, and IOP) that
were repeatedly measured during the follow-up period, a mixed model analysis was
performed. The analysis considered the different groups, the assessment time points, and
the interaction between these two parameters as fixed effects, and individual patients
as random effects [17]. In the subgroup analysis of different implantation number, the
paired-sample t-test was used to evaluate changes in LogMAR VA, IOP, and CRT values
between baseline and other time points in cases of normal distribution. No missing data
substitutions were made; missing data were excluded pairwise in all tests. A p-value < 0.05
was regarded as statistically significant. Statistical analyses were calculated using SPSS
Statistics for Windows software version 24 (IBM Corporation, Armonk, NY, USA).
3. Results
3.1. Demographic and Population Characteristics
Demographic and baseline characteristics of the study population are shown in Table 1.
In this study, 73.0% of the patients were women, and the most common inflammatory
diseases were idiopathic uveitis (34.6%), followed by Behcet’s disease (17.3%), juvenile
idiopathic arthritis (13.5%), Vogt–Koyanagi–Harada syndrome (9.6%), and acute anterior
uveitis (9.6%) (Table 1). In this study, 94.2% of the patients received systemic steroid therapy, 36.5% received topical steroid eye drops prior to dexamethasone implantation, 78.8%
of the patients received previous posterior sub-tenon triamcinolone (Triamcinolone Suspended Injection, Tai Yu Chemical & Pharmaceutical Co., Hsinchu, Taiwan) injection, 65.4%
received previous disease-modifying antirheumatic drugs, and 64.7% were pseudophakic
at baseline. During the mean follow-up period of 11.54 months, 24 eyes (46.2%) received
one implant, 15 eyes (28.8%) received two implants, seven eyes (13.5%) received three
implants, and three eyes (5.8%) received four or more implants. The criteria for multiple
implants included (1) macular edema was not related to other pathology such as epiretinal
membrane formation, (2) previous injections had therapeutic responses to macular edema
without severe adverse effects such as retinal detachment, (3) the patient agreed and could
afford to have the dexamethasone implant. The reinjection of dexamethasone implant was
applied at recurrence of macular edema, 6 months after the previous injection. Baseline
values of the outcome measurements are also reported in Table 1.
3.2. A Single DEX Implant Improved VA and Decreased CRT
Compared to baseline, significant VA improvement, expressed as LogMAR VA, occurred at both one and two months after the first DEX implant (p < 0.01 vs. baseline;
Figure 1a). There was also a significant decrease in CRT one month after the first DEX
implant (p < 0.001), and it remained significantly lower for six months when compared to
baseline values (all p < 0.001; Figure 1b).

Figure 1. The change in (a) LogMAR visual acuity and (b) central retinal thickness from baseline after
the 1st intravitreal dexamethasone implantation at different time points. Values represent mean ± SD.
p < 0.05 were considered statistically different. ** p < 0.01, *** p < 0.001.
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3.3. Multiple DEX Implants Decrease CRT but Have No Change on VA
To further analyze the visual outcomes, patients were divided into four groups based
on the number of DEX implants (one, two, three, and more than three). Results showed
that VA did not change significantly after multiple DEX implants, but a gradual regression
to baseline values was noted (Figure 2a). However, CRT showed a significant decrease
one month after each DEX implant (p < 0.001 vs. baseline at each time point; Figure 2b) in
patients who received more than one implant. Notably, in eyes receiving only one DEX
implant, the reduction in CRT from baseline was significant and this effect persisted for 3
and 6 months.

Figure 2. The change in (a) LogMAR visual acuity and (b) central retinal thickness from baseline
after the intravitreal dexamethasone implantation based on the number of implantations at different
time points. Values represent mean ± SD. p < 0.05 were considered statistically different. * p < 0.05,
** p < 0.01, *** p < 0.001.

3.4. Intraocular Pressure Increases as a Marker of Adverse Effects
To evaluate the occurrence of adverse effects due to DEX implants, IOP was assessed
after each administration. We only observed an increase in IOP compared with baseline
values at the first month after a single DEX implant (p < 0.05; Figure 3a). All eyes with
elevated IOP were controlled with topical IOP-lowering eye drops for at least one month,
without the need for IOP-lowering laser or incisional surgery. However, in the eyes that
received more than one DEX implant, IOP did not change significantly at any time point
throughout the whole study (Figure 3b). These results suggest that IOP increase due to
a single DEX implant was only evidenced after one month, but this effect did not persist
during the whole study. Thus, this indicates that DEX implants do not produce long-lasting
significant adverse effects. If the patient had elevated IOP after receiving the DEX implant,
they would not receive further implants as their IOP would require an evaluation period
longer than one month. However, topical medication could be used to manage it.

Figure 3. The change in intraocular pressure from baseline (a) after the 1st intravitreal dexamethasone
implantation and (b) after the intravitreal dexamethasone implantation based on the number of
implantations. Values represent mean ± SD. p < 0.05 were considered statistically different. * p < 0.05,
*** p < 0.001.
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4. Discussion
This study demonstrated that DEX implants improved VA and CRT, suggesting
beneficial effects in the treatment of refractory ME in eyes with noninfectious uveitis. To
date, there are few studies on DEX treatment in refractory uveitic ME. To the best of our
knowledge, this is the first real-world study in Taiwan, where the etiology of uveitis is
different from that in Western countries, with a higher incidence of juvenile idiopathic
arthritis [16], Vogt–Koyanagi–Harada syndrome, and Behcet’s disease [18]. Although some
of our findings have been reported previously, the effect of dexamethasone in refractory
uveitic ME has not been well investigated in Asian populations, which may have a different
response to steroid treatment. In addition, this was a real-world study with a long follow-up
period and included patients with multiple DEX implants.
In 2011, the Ozurdex HURON study group reported that VA improved after a single
DEX implant in eyes with noninfectious uveitis, and that improvement was sustained
for up to six months [19]. Later, investigators found that intravitreal DEX implants were
effective in treating refractory uveitic ME [20], and in a multicenter, retrospective cohort
study using DEX implants in eyes with noninfectious uveitis, a significant improvement
in VA, central foveal thickness, and vitreous haze was reported, and the effects lasted
for at least six months [21]. Other studies described positive outcomes one month after
DEX implants, which remained for six months [10,19,22]. However, a shorter recurrence
interval (five months) was reported in vitrectomized eyes with uveitic ME, and a DEX reimplantation interval between four and six months was suggested in this condition [23,24].
In accordance, our results showed that VA significantly increased one and two months
after a single DEX implant administration and that this effect remained for six months.
However, when patients were divided into different subgroups based on the number of
implants, VA did not show significant differences between groups with more than one
implant. This might be due to the lower number of eyes in each subgroup and a broader
variation in VA, though an improving trend and the gradual regression of VA to baseline
values was evidenced after DEX implants.
Changes in VA are mainly related to changes in CRT [25,26]. Numerous clinical studies
have demonstrated that CRT improves after DEX implant [27–29]. In eyes with uveitic
ME, mean CRT was reduced after DEX implants with respect to baseline values, and that
improvement was sustained for up to six months [14,30]. In this regard, our results on
CRT are in agreement with previous studies that demonstrated that DEX implants had a
significant effect on reducing CRT in eyes with uveitis [10,25,31]. The finding of a decreased
CRT correlates with the improvement in VA observed in the eyes of the patients one month
after the DEX implant.
Although the observed effect was different one and two months after the DEX implant,
we observed a trend in VA improvement that continued for up to six months. These results
may be due to the small case number in late follow-up visits. On the other hand, CRT
remained significantly low six months after DEX implants. For patients with a single
injection, we have followed the biomarkers for up to 24 months (shown in Supplementary
Figure S1), and found the CRT improvement could last for 24 months. However, the trend
in VA improvement was not observed after the 6th month. Because patients with cataracts
were not excluded from the study, the progression of cataracts may have affected VA results
in late follow-up visits. Additionally, we did not compare the changes in cataract condition
due to the retrospective nature of the study. In this regard, patients may be followed by
different ophthalmologists in a single center, and it is known that the cataract grading
depends on the ophthalmologist’s criteria.
In patients with a single implant, remission of macular edema was observed in 20 of
24 eyes (83.3%) during the follow-up period. In patients with multiple implants, remission
of macular edema was observed in 20 of 28 eyes (71.4%). For eyes with recurrent macular
edema, patients were either lost to follow-up, refused multiple implants, or, because of
financial difficulties, dexamethasone implants were not continued. All the eyes in this study
with multiple implants had therapeutic responses during the previous implant treatment
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based on our multiple-implantation criteria. For patients observed to have a good response
to the previous dexamethasone implantation, we do suggest consideration of a repeat
injection. However, the maximal number of implants has not been investigated. As for
determination of responses, the investigation to predict biomarkers for the recurrence of
uveitic macular edema is ongoing
DEX is a well-known corticosteroid widely used in the treatment of inflammatory
diseases, including uveitis. Systemic and topical administration of corticosteroids and
nonsteroidal anti-inflammatory drugs are common treatments and have proved effective in
uveitic ME [32]. However, systemic steroids are frequently associated with multiple adverse
effects [24]. Adverse side effects due to systemic steroid therapy include hyperglycemia,
arterial hypertension, and weight gain, and they can increase IOP and cause cataracts [24].
However, in a three-year clinical trial, DEX implants showed a transient and controlled but
not cumulative increase in IOP in eyes from patients with diabetic ME [33]. In accordance,
DEX implants produced a rise in IOP within the first two weeks [34] and during the two
months post-injection [35], but gradually decreased after 12 months. In line with these
findings, our results demonstrated that IOP increases were observed only at 1 month
after DEX administration, and the IOP could be controlled afterward. In our study, a
non-invasive medical intervention was performed to control IOP and to treat elevated IOP.
Given that transient IOP elevation may still be harmful in some patients, especially to treat
those with pre-existing glaucoma, a close and regular IOP follow-up remains crucial after
DEX implants, mainly two months after the injection.
To avoid inter-eye correlations, we performed a subgroup analysis which included
only one eye from each patient (shown in Supplementary Figure S3). The results from the
subgroup had comparable findings with the overall group using the eye as the unit. It may
indicate that the effect of inter-eye correlations could be alleviated in the study analyzed
using the longitudinal model using the eye as the unit of analysis [36].
DEX demonstrated efficacy in noninfectious uveitis in the HURON clinical trial, as
evidenced by controlled intraocular inflammation for at least six months, together with
a significant improvement in VA and decreased vitreous haze score and central foveal
thickness [16]. Although the observed effects of multiple implant administrations were
similar to those obtained solely with the first implant [36], the recommended interval
between administrations is four to six months [24]. This may be reasonable in terms of
efficacy, therapy duration, and the risk of adverse effects. Close follow-up and monitoring
of adverse effects such as elevation of IOP and formation of cataracts were also emphasized
in patients with multiple DEX implants [37].
However, there are limitations to this study inherent to its retrospective nature. In
addition, some patients did not come back for follow-up, and the study had a small number
of cases, especially after subdivision into smaller groups. The small number may affect
the statistical significance, though the effect of repeated DEX implants appeared to be
similar to the first injection. In our study, we did not include any power analysis due to our
study design and population entity. In this regard, the population may be limited in case
numbers compared to other ocular conditions; however, we included all eyes receiving
DEX implants for refractory uveitic macular edema. Thus, the total number of eyes in the
present study was higher when compared to similar previous studies [14,15]. Therefore, the
results may still be able to demonstrate the real-world data for patients with uveitic macular
edema treated with DEX implants. For IOP, results might exhibit a selection bias because
the patients with elevated IOP after injection would not further receive DEX implants. The
comparison of systemic side effects, as well as the analyses of systemic anti-inflammatory
treatment, were not performed, resulting in the absence of potential/probable correlations
in eyes that did not respond to DEX implants. Still, our study provides real-world results of
intravitreal DEX implants in eyes with refractory ME in noninfectious uveitis. In addition,
most studies on uveitic ME treated with DEX implants are short-term, retrospective studies
with a limited number of eyes. Randomized studies are needed to evaluate the use of
multiple DEX implants and to assess the long-term effects of repeated implants on IOP and
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the consequent cataract formation. Additionally, it is necessary to determine whether early
treatment with DEX implants may be beneficial in reducing the adverse effects associated
with systemic immunosuppressive treatments.
5. Conclusions
In conclusion, DEX implants are effective for eyes with refractory uveitic ME. However,
while visual acuity appears to remain stable over the six months following an injection, the
improvement in CRT seen in the first month fades over time.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/jcm10173762/s1, Figure S1: The 24-month longitudinal change of (a) LogMAR visual acuity,
(b) central retinal thickness, and (c) intraocular pressure in patients received single dexamethasone
injection. * p <0.05, ** p <0.01, *** p <0.001; Figure S2: The Q-Q plots and results of Shapiro–Wilk
test in patient’s baseline LogMAR visual acuity, central retinal thickness, and intraocular pressure.;
Figure S3: The change in (a) LogMAR visual acuity, (b) central retinal thickness, and (c) intraocular
pressure in subgroup with 37 eyes from the 37 patients. * p <0.05, *** p <0.001.
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